Head and neck squamous cell carcinoma (HNSCC) exhibits limited response to EGFR blockade with cetuximab, largely due to constant activation of the PI3K/AKT/mTOR pathways. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.